Navigation Links
STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
Date:11/28/2007

ANTONY, France, November 28 /PRNewswire-FirstCall/ -- The results of a study on children confirmed the efficacy of the ORALAIR(R) Grasses sublingual desensitisation product, which is due to receive German market authorisation shortly.

The phase III paediatric study, VO52.06, which was carried out on 280 patients in 5 European countries suffering from allergic rhino-conjunctivitis, fully met the main evaluation criterion by demonstrating a statistically significant reduction in symptoms, comparable to that observed in the VO34.04 adult study.

Based on this study, STALLERGENES will request the indication of the ORALAIR(R) Grasses market authorisation to be extended to children.

In addition, results of the first long term adult study (VO53) will be available by the end of the year.

STALLERGENES is confident in the commercial launch of ORALAIR(R) Grasses in Europe.

At the same time, as part of the Company's expansion in the US, the proposal for two phase III clinical studies in the US (adults and children), planned for 2009, was received favourably by the FDA and American experts. Talks with potential partners are ongoing.

All these items will be subject to an information meeting on 10 December 2007.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitization treatments for the prevention and cure of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma.

Pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 18% of its sales to Research and Development and is today fully involved in the development of a new therapeutic family, the sublingual desensitization tablets.

STALLERGENES realised 2006 sales of EUR 126.5 million, primarily from European markets.

Stallergenes' shares are listed on Eurolist Compartment B of the Euronext Paris Stock Exchange.

ISIN code: FR0000065674, Reuters code: GEN.PA, Bloomberg code: GEN.FP

Additional information on STALLERGENES is available on our website: http://www.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
7. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
9. Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
10. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
11. Blood Donations in U.S. Testing Positive for Chagas Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016 On Monday, the ... to industry to share solutions for the Biometric Exit ... Customs and Border Protection (CBP), explains that CBP intends ... departing the United States , in ... to defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
Breaking Biology News(10 mins):